Sea Creation Pharmaceuticals (688302.SH) has completed the first subject's enrollment in China's clinical trial of its self-developed drug HP515.
Hichip Pharmaceuticals (688302.SH) announced that the company's independently developed HP515 tablets are used to treat non-alcoholic fatty...
Haisco Pharmaceutical (688302.SH) announced that the clinical trial of the company's independently developed HP515 tablets for the treatment of non-alcoholic steatohepatitis (NASH) recently completed the first subject enrollment.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
